Articles about 'spin-out'

Researchers have created a plant-based, sustainable, scalable material that could replace single-use plastics in many consumer products.

British duo Professor Shankar Balasubramanian and Professor David Klenerman have been awarded the Millennium Technology Prize for their development of revolutionary DNA sequencing techniques.

Professor Laura Itzhaki is a group leader in the Department of Pharmacology and a Fellow of Newnham College. Here, she tells us about forming her own spin-out company, pitching to investors and her research on the 'workhorses' of the cell. 

A recent University of Cambridge spin-out company, Paragraf, has started producing graphene – a sheet of carbon just one atomic layer thick – at up to eight inches (20cm) in diameter, large enough for commercial electronic devices. 

Researchers from the UK and Denmark have developed a new method to predict the physical stability of drug candidates, which could help with the development of new and more effective medicines for patients. The technology has been licensed to Cambridge spin-out company TeraView, who are developing it for use in the pharmaceutical industry in order to make medicines that are more easily released in the body. 

What makes a city as small as Cambridge a hotbed for AI and machine learning start-ups? A critical mass of clever people obviously helps. But there’s more to Cambridge’s success than that. 

Andy Neely is Cambridge’s Pro-Vice-Chancellor for Enterprise and Business Relations, a role which oversees the University’s activities in innovation, commercialisation and entrepreneurship. After six months in the role, he sees an entrepreneurial ecosystem that may appear complex at first – but a deeper examination reveals a combination of knowledge, expertise, support and infrastructure that makes Cambridge one of the most enterprising and entrepreneurial cities in the world. 

Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.

A University of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease. 

Cambridge spin-out Carrick Therapeutics raises $95 million in funding, representing the largest-ever early stage investment in a UK university spin-out company.